Biopharma teams don’t lose deals because they lack ambition. They lose because they’re late to the timeline.
In licensing, partnering, and commercial strategy, timing is everything—especially when the product isn’t just a molecule, but a full system: f…

OpenAI’s “GPT for life sciences” is getting the headlines. But the real question isn’t whether the model can read papers—it’s whether it can change the economics of drug development.
That’s the tension at the heart of the latest wave of AI coverage aro…

Patent expiry intelligence isn’t just for lawyers anymore—it’s for operators who want to win the biosimilar race.
Most teams treat biosimilar commercialization like a calendar event: track patent cliffs, wait for the legal dust to settle, then start ou…

Drug patents in Europe: the clock is ticking—and it doesn’t always run the way companies expect.
If you’re building a pipeline, funding R&D, or underwriting risk, the question isn’t just “Do we have patent protection?” It’s “How long will it actual…

Drug discovery is stuck in molasses. GPT + Rosalind could be the first real shortcut.
If you’ve worked anywhere near pharma R&D, you already know the punchline: timelines are long, costs are brutal, and the “science” is often bottlenecked by the un…

The “Patent Expiration Cliff” Isn’t a Cliff—It’s a Calendar. Here’s How Commercial Market Access Teams Can Sell Before the Drop.
If you’ve worked in commercial market access long enough, you’ve seen the same pattern: a brand’s exclusivity window tighte…

Authorized Generics: The Innovator’s Playbook for Diluting First-Filer Profits
The first-filer advantage is supposed to be a moat. File early, win the patent fight, capture the exclusivity premium—repeat. But the market has a way of turning “wins” into…

Read the Clock Right: Mapping Regulatory Exclusivities for True Generic Drug Entry Timing
The difference between a true generic launch and a delayed “me-too” entry is often not science—it’s timing.
In today’s branded-to-generic transition, the market d…

Unlocking the Hidden Clock: How Precise Mapping of Regulatory Exclusivities Can Accelerate Generic Drug Entry
In the complex world of pharmaceutical innovation and market competition, timing is everything. Yet, for many stakeholders—manufacturers, inve…

The real “winner” in pharma patent litigation isn’t always the one with the strongest science—it’s the one who understands timing.
Generic entry is supposed to be the market’s reset button: once patents expire, competition should lower prices and expan…